NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in PayPal Holdings, Inc. ("PayPal" or the "Company") (NASDAQ: PYPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PayPal investors who were adversely affected by alleged securities fraud between February 25, 2025 and February 2, 2026. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/paypal-holdings-inc-l ...

LOS ANGELES, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Preferred Bank (NASDAQ: PFBC), (“the Bank”), an independent commercial bank, provided an update on a large loan relationship. In the fourth quarter of 2025, the Bank announced that it had downgraded a large relationship totaling $2.0 million in commercial and industrial (C&I) loans and $115.6 million of real estate loans to substandard classification. Due to the principals of the relationship being involved in several complicated lawsuits with other banks which ...

Achieved 2025 financial results at the top end of the original guidance rangeFleet Enhancement program advanced with repowerings for 2026/2027 on scheduleSponsor Enabled growth program advanced with signed agreements with Clearway Group to commit to remaining planned 2026 COD projects with 291 MW storage portfolio in Colorado and CaliforniaOutlook for sponsor enabled growth advanced further into 2027 and 2028 with receipt of offer to invest in 520 MW Royal Slope solar plus storage project and 650 MW Swan So ...

MIDLAND, Texas, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ:VNOM) (“Viper,” “we,” “our” or the “Company”), a subsidiary of Diamondback Energy, Inc. (NASDAQ:FANG) (“Diamondback”), today announced financial and operating results for the fourth quarter and full year ended December 31, 2025. FOURTH QUARTER HIGHLIGHTS Q4 2025 average production of 66,413 bo/d (134,000 boe/d)Q4 2025 consolidated net loss (including non-controlling interest) of $246 million; net loss attributable to Viper of $103 ...

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader bri ...

CARLSBAD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 2026 Canaccord Genuity Musculoskeletal Conference on March 2, 2026 at 11:30 AM CST in New Orleans, LA.   A live webcast will be available to registered participants. Following the presentation, the webcast replay will be available at https://event.summitcast.com/view/d69xRqMspwymhwGUDdQoes/JC9qqvWhWggYawxGnDNtmz Abo ...

Core Insights - Skyward Specialty Insurance Group reported a significant increase in net income for Q4 2025, reaching $43.2 million, or $1.03 per diluted share, compared to $14.4 million, or $0.35 per diluted share in Q4 2024 [1][20] - For the full year 2025, net income was $170.0 million, or $4.07 per diluted share, up from $118.8 million, or $2.87 per diluted share in 2024 [1][20] Financial Performance - Adjusted operating income for Q4 2025 was $48.9 million, or $1.17 per diluted share, compared to $33.2 million, or $0.80 per diluted share in Q4 2024, marking a substantial year-over-year increase [2][21] - The full year adjusted operating income for 2025 was $167.4 million, or $4.00 per diluted share, compared to $126.6 million, or $3.06 per diluted share in 2024 [2][21] Underwriting Results - Gross written premiums for Q4 2025 were $439.5 million, a 13.2% increase from $388.4 million in Q4 2024, while total gross written premiums for the year reached $2.17 billion, up 24.3% from $1.74 billion in 2024 [3][5] - The combined ratio improved to 88.5% in Q4 2025 from 95.8% in Q4 2024, indicating better underwriting performance [4][5] Investment Results - Net investment income for Q4 2025 increased to $23.5 million from $20.7 million in Q4 2024, driven by higher yields from the fixed income portfolio [7][20] - For the full year, net investment income rose to $83.6 million from $80.6 million in 2024 [7][20] Equity and Book Value - Stockholders' equity increased to $1,009.6 million at December 31, 2025, a 5.0% rise from $961.4 million at September 30, 2025, primarily due to net income and an increase in the market value of the investment portfolio [9][26] - Book value per share reached $24.92, reflecting a 26% increase compared to $19.79 at the end of 2024 [5][22] Strategic Outlook - The company emphasized its "Rule Our Niche" strategy, focusing on a diversified portfolio with nearly half of its business in non-cycle exposed lines, positioning it well for future growth in the specialty insurance market [2][5]

Strategic reset positions Galapagos for long-term value creation Robust 2025 year-end cash and financial investments of €3.0 billion and ongoing collaboration with Gilead enable flexibility to execute on a business development-led growth strategy 2026 year-end cash expected to be in the range of €2.775 to €2.850 billion, with reduced cell therapy one-time restructuring cash costs of €25 million to an updated range of €125 to €175 million Management to host conference call tomorrow, February 24, 2026, at 14: ...

Welcomes Long-Overdue Acknowledgment of Stockholder Concerns Calls for Recusal of 10X-Affiliated Directors from AMA Discussions and Full Public Disclosure of Proposed AMA Amendments Reaffirms the Importance of Board Independence and Protection of Stockholder Rights ROAD TOWN, British Virgin Islands, Feb. 23, 2026 (GLOBE NEWSWIRE) -- YZILabs Management Ltd. (“YZi Labs”, “YZi”, “we”), a significant stockholder of CEA Industries Inc. (NASDAQ: BNC) (“BNC” or the “Company”), today issued the below statement in r ...

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program on an investor webcast on Tuesday, February 24, 2026, at 8:00 a.m. ET.The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be ...